Short Interest in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Declines By 63.1%

Posted by Trevor Kearing on Dec 26th, 2024

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 83,700 shares, a drop of 63.1% from the November 30th total of 226,700 shares. Based on an average daily trading volume, of 449,700 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.5% of the shares of the company are sold short.

Sensei Biotherapeutics Trading Up 2.2 %

SNSE stock traded up $0.01 during mid-day trading on Thursday, hitting $0.46. The stock had a trading volume of 33,610 shares, compared to its average volume of 205,859. The firm has a fifty day simple moving average of $0.51 and a 200 day simple moving average of $0.57. The firm has a market capitalization of $11.67 million, a P/E ratio of -0.39 and a beta of 0.16. Sensei Biotherapeutics has a 52 week low of $0.38 and a 52 week high of $1.94.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI boosted its position in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Free Report) by 355.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

About Sensei Biotherapeutics

(Get Free Report)

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.